Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1828571 | 0.85 | GRM2 (0.54) | GRM2 | |
| SCHEMBL1827879 | 0.83 | GRM2 (0.59) | GRM2 | |
| SCHEMBL1828011 | 0.80 | LMNA (0.57) | GRM2 | |
| SCHEMBL8146318 | 0.78 | GRM2 (0.41) | GRM2ACHE | |
| SCHEMBL1830288 | 0.77 | GRM2 (0.51) | GRM2 | |
| SCHEMBL171281 | 0.75 | GRM2 (0.64) | GRM2 | |
| SCHEMBL171863 | 0.71 | GRM2 (0.46) | GRM2 | |
| SCHEMBL25331540 | 0.70 | LMNA (0.59) | GRM2 | |
| SCHEMBL1828629 | 0.68 | GRM2 (0.57) | GRM2 | |
| SCHEMBL169742 | 0.66 | ALDH1A1 (0.44) | GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8906939-B2 | 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives | Janssen Pharmaceuticals, Inc. (US) | 2014-12-09 | — | — | US | disclosed |
| US-8906939-B2 | 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives | Janssen Pharmaceuticals, Inc. (US) | 2014-12-09 | — | — | US | disclosed |
| US-8906939-B2 | 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives | Janssen Pharmaceuticals, Inc. (US) | 2014-12-09 | — | — | US | disclosed |
| US-8796311-B2 | — | — | 2014-08-05 | — | — | US | disclosed |
| US-8796311-B2 | — | — | 2014-08-05 | — | — | US | disclosed |
| US-8796311-B2 | — | — | 2014-08-05 | — | — | US | disclosed |
| CN-101711244-B | 3-cyano-4- (4-tetrahydropyran-phenyl) -pyridin-2-one derivatives | JANSSEN PHARMACEUTICA NV | 2013-01-16 | — | — | CN | disclosed |
| EP-2134708-B1 | 3-CYANO-4-(4-TETRAHYDROPYRAN-PHENYL)-PYRIDIN-2-ONE DERIVATIVES | ORTHO MCNEIL JANSSEN PHARM (US) | 2011-05-11 | — | — | EP | disclosed |
| CN-101711244-A | 3-cyano-4- (4-tetrahydropyran-phenyl) -pyridin-2-one derivatives | JANSSEN PHARMACEUTICA NV | 2010-05-19 | — | — | CN | disclosed |
| US-20100087487-A1 | 3-CYANO-4-(4-TETRAHYDROPYRAN-PHENYL)-PYRIDIN-2-ONE DERIVATIVES | Ortho-McNeil Janssen Pharmaceuticals Inc. (US) | 2010-04-08 | — | — | US | disclosed |
| US-20100087487-A1 | 3-CYANO-4-(4-TETRAHYDROPYRAN-PHENYL)-PYRIDIN-2-ONE DERIVATIVES | Ortho-McNeil Janssen Pharmaceuticals Inc. (US) | 2010-04-08 | — | — | US | disclosed |
| US-20100087487-A1 | 3-CYANO-4-(4-TETRAHYDROPYRAN-PHENYL)-PYRIDIN-2-ONE DERIVATIVES | Ortho-McNeil Janssen Pharmaceuticals Inc. (US) | 2010-04-08 | — | — | US | disclosed |
| EP-2134708-A1 | 3-CYANO-4-(4-TETRAHYDROPYRAN-PHENYL)-PYRIDIN-2-ONE DERIVATIVES | Ortho-McNeil-Janssen Pharmaceuticals, Inc. (US) | 2009-12-23 | — | — | EP | disclosed |
| WO-2008107481-A1 | 3-CYANO-4-(4-TETRAHYDROPYRAN-PHENYL)-PYRIDIN-2-ONE DERIVATIVES | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC (US) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087487-A1 | 3-CYANO-4-(4-TETRAHYDROPYRAN-PHENYL)-PYRIDIN-2-ONE DERIVATIVES | GRM2, GRM3, GRIK2 | GRM2 1/4885ACHE 1276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.